Key Points
- Biosig Technologies Chairman Morgan Lee Lekstrom bought 34,000 shares on May 28 at an average price of $1.47, increasing his stake by 12.36% to 309,000 shares.
- The purchase followed a much larger insider buy a week earlier, when Lekstrom acquired 147,000 shares at $1.04; he also sold 12,759 shares in April.
- The stock recently traded around $1.51, far below its 52-week high of $14.11, while analysts currently have an average Hold rating with an $8.00 consensus target.
Biosig Technologies, Inc. (NASDAQ:STEX - Get Free Report) Chairman Morgan Lee Lekstrom acquired 34,000 shares of the stock in a transaction on Thursday, May 28th. The shares were acquired at an average cost of $1.47 per share, for a total transaction of $49,980.00. Following the completion of the transaction, the chairman directly owned 309,000 shares in the company, valued at $454,230. The trade was a 12.36% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
Morgan Lee Lekstrom also recently made the following trade(s):
- On Thursday, May 21st, Morgan Lee Lekstrom acquired 147,000 shares of Biosig Technologies stock. The shares were acquired at an average cost of $1.04 per share, for a total transaction of $152,880.00.
- On Tuesday, April 14th, Morgan Lee Lekstrom sold 12,759 shares of Biosig Technologies stock. The stock was sold at an average price of $1.07, for a total transaction of $13,652.13.
Biosig Technologies Price Performance
Shares of Biosig Technologies stock opened at $1.51 on Friday. Biosig Technologies, Inc. has a 1 year low of $0.70 and a 1 year high of $14.11. The stock has a market cap of $274.52 million, a P/E ratio of -0.16 and a beta of 1.58. The stock's fifty day simple moving average is $1.13.
Biosig Technologies (NASDAQ:STEX - Get Free Report) last released its earnings results on Thursday, May 14th. The company reported ($0.27) EPS for the quarter.
Analyst Ratings Changes
STEX has been the subject of several recent analyst reports. Needham & Company LLC reduced their target price on shares of Biosig Technologies from $9.00 to $8.00 and set a "buy" rating for the company in a research note on Thursday, May 21st. Wall Street Zen cut shares of Biosig Technologies from a "hold" rating to a "strong sell" rating in a research note on Sunday, April 5th. Finally, Weiss Ratings upgraded shares of Biosig Technologies from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Friday, May 1st. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $8.00.
Get Our Latest Analysis on Biosig Technologies
About Biosig Technologies
(
Get Free Report)
Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.
Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
